Atopic Dermatitis is a type of inflammation of the skin that affects a large percentage of the world’s population. It is estimated that at least 20% of people will be affected by Atopic Dermatitis at some point in their lives. The condition typically starts in childhood with changing severity over the years. There is no known cure for Atopic Dermatitis although treatments can affect the severity and frequency of flare-ups.
High-quality samples are paramount in developing new treatments for Atopic Dermatitis. HemaCare sources, isolates, and ships human samples under rigorously controlled protocols to provide the optimum starting material for your research.
Patients diagnosed with Atopic Dermatitis are recruited as volunteer donors for research products. They review and sign an independent biomedical review board (IRB) approved procedure-specific consent form prior to the collection.
Either prepare cells for long-term storage in Liquid Nitrogen vapor phase or thaw for use. Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately.
Testing: Donors are tested for HBV, HCV, and HIV, unless requested otherwise.
PBMC Flow Data
Please note that the frequency of cell type via principal markers is highly variable and can be significantly influenced by the type of disease, medication prescribed to the donor, and how the donor reacts to the medication. These graphs and their subsequent cell frequencies are representative sample and are not indicative of received samples.